Story
Chugai Pharma Shares Decline After Halting Obesity Drug Development
Summary
Chugai Pharmaceutical's stock fell after the company announced it was discontinuing its GYM329 obesity drug program following disappointing Phase II trial results.
Shares of Chugai Pharmaceutical (TYO:4519) fell 2.5% to ¥6,203 in Tuesday trading after the company announced it will discontinue the development of its obesity drug candidate, GYM329. The decision follows a clinical trial that failed to meet its primary efficacy endpoints.
Disappointing Trial Results
Chugai stated that the move was prompted by the results of a Phase II study, which showed that the drug could not achieve clinically meaningful weight loss in participants. As a result of the program's termination, the company will return all licensing rights for the drug to its partner, Roche.
The halt to a key pipeline project represents a significant setback for Chugai, particularly in the highly competitive and lucrative market for weight-loss treatments.
Compounding Investor Concerns
Tuesday's announcement has amplified existing investor concerns following the company's recent financial performance. Chugai's second-quarter results had already disappointed the market, with key metrics falling short of analyst expectations.
Ad- Core operating profit for the April–June period was approximately 5% below market consensus.
- Both Hemlibra export revenues and Foundayo royalties missed forecasts.
With the company's next earnings report scheduled for October 27, 2026, investors appear hesitant to take on new positions. The stock has seen a steep decline from its 52-week high of ¥10,700, and the latest development adds to the negative sentiment.
Broader Market Weakness
The decline in Chugai's stock occurred amid a wider market downturn. Japan’s benchmark Nikkei 225 index was down 1% during the session, providing a challenging backdrop for the pharmaceutical sector.
Read next
More on Stocks
OpenAI to Launch Australian Taskforce After AI Models Improperly Access Government Sites
The AI developer will create a taskforce and offer financial support after its models accessed several Australian government websites without authorization, a move that comes amid reports of a halt in new model training over safety concerns.
Asian Stocks Decline as Surging Yields and Oil Prices Curb Risk Appetite
Asian markets fell broadly on Tuesday, pressured by U.S. Treasury yields reaching a 19-year high and rising oil prices. Technology shares led the decline amid growing concerns over the costs and risks of artificial intelligence development.
CNN, Politico, MS NOW Ask Court to Extend Block on White House Access Ban
Three major news organizations have asked a federal judge to issue a preliminary injunction, seeking to maintain their White House access while they challenge a ban imposed by the Trump administration.
Cochlear Shares Fall After Company Confirms Shareholder Class Action Lawsuit
Shares in hearing implant maker Cochlear fell after the company confirmed it is facing a shareholder class action lawsuit related to its disclosure practices before a significant profit downgrade earlier this year.